By Dennis Thompson
THURSDAY, June 6 (HealthDay News) -- The controversial diabetes drug Avandia will get a second look from federal regulators this week, nearly two years after its use was severely restricted because of a link to heart problems.
The U.S. Food and Drug Administration has convened a panel of experts to consider an independent review by Duke University researchers of Avandia's original clinical trial. The expert panel will conclude its sessions on Thursday, and could decide to alter or even lift the tight restrictions now in place regarding the medication's use.
The Duke scientists did uncover some previously unreported cases of heart complications and deaths, but concluded that these cases did not significantly raise the overall risk of heart disease and the conclusions of the original trial still hold.
The FDA's reconsideration of Avandia's safety has prompted stinging criticism from the drug's detractors, who say the agency is trying to save face following a very public embarrassment over the drug.
"This is a drug that has essentially been off the market in almost the entire world for the last three years. It has been banned in most countries, and is available in the United States under such strict requirements that only 3,000 patients now take it," said Dr. Steven Nissen, the Cleveland Clinic cardiologist who first led the charge against Avandia. "It's really about the FDA wanting to clean up its image, not about whether the drug is actually safe or unsafe."
The FDA has defended its decision to review the Duke re-analysis of the original trial, which was conducted by the drug's maker, GlaxoSmithKline, under the name Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD).
"Given the public interest in Avandia, the extensive history of the product and the continued uncertainty of risk, the FDA is holding the advisory committee meeting to have a transparent, public discussion of the results of the RECORD readjudication," FDA spokesperson Morgan Liscinsky said.
Avandia quickly became a blockbuster diabetes drug following its release in 1999, with sales topping $3 billion in 2006.
But in 2007, Nissen published a study showing that Avandia raised the risk of heart attack by more than 40 percent. The outcry that followed led to Senate hearings in which the FDA's drug approval process came under intense scrutiny.
An FDA analysis of more than 50 studies of Avandia found that the drug was linked to an increased risk of heart problems. One study tied Avandia use to more than 47,000 cases of heart attack, stroke or heart failure during a 10-year period, even though the company-funded RECORD trial had not found an increased risk of cardiovascular trouble.
The FDA ended up pulling Avandia from pharmacy shelves in November of 2011, placing severe restrictions on the drug that limited its use to extremely ill diabetics. Patients wanting to take the medication now must enroll in a special program to qualify for its use.
Critics call this week's meetings a waste of taxpayer dollars, arguing that so many concerns have been raised about Avandia's safety that a green light now from the FDA would be meaningless.
"It's not an issue of any importance to the medical community," Nissen said. "It's all about the FDA. If the FDA is allowed to whitewash the Avandia affair, it makes it less likely the right thing will be done when issues like this come up in the future," he added.
"Unfortunately, the public is caught in the crossfire," he continued. "The last thing we want to do is promote the use of an agent that is not helpful and is almost certainly harmful in the majority of the people who take it."
Nissen and other critics noted that the Duke review was funded by GlaxoSmithKline and have questioned the independence of the follow-up research.
A panel of FDA officials have vouched for the Duke report, however, and argue that its findings deserve scrutiny in a public forum.
"The FDA strongly believes that regulatory decisions should be based on strong scientific evidence. If such evidence becomes available to revisit previous regulatory decisions, it is important for the FDA to consider this evidence in a transparent process," Liscinsky said. "The FDA is critically evaluating the RECORD readjudication. Once the advisory committee meeting has been held and review is complete, the FDA will determine if the results of the readjudication in the context of all the pertinent available data affect the agency's assessment of the risk-benefit information for rosiglitazone [Avandia]."